Telix Pharmaceuticals signed an agreement on September 20 to buy all of ITM for US$1.65 billion in cash, on a cash-free, debt-free basis. Telix will also hand over roughly US$1.25 billion in its own shares, priced at US$11.84 each, and absorb about US$302 million of ITM's net debt. A further US$700 million sits in escrow, payable only if ITM-11 hits certain milestones. Nothing has closed. Telix says shareholder and regulatory approvals remain outstanding, which means the number investors see today is a ceiling, not a settled price.
The headline price, near US$2.35 billion before the contingent tranche, lands at a moment when radiopharmaceutical assets have become scarce and expensive. Buyers are paying up for isotope supply chains and clinical-stage diagnostic or therapeutic pairs rather than waiting for them to mature internally. That backdrop makes the structure of this deal as important as its size. Cash covers most of the upfront, shares cover a third, and debt assumption adds another layer, which together determine how much dilution current Telix holders absorb versus how much leverage the combined company carries into integration.
For investors, the fixed share price of US$11.84 is the detail to watch. If Telix's stock trades meaningfully above or below that level before closing, the economics of the deal shift for both sides without the headline figure changing. ITM shareholders took a locked-in valuation; Telix shareholders took on dilution risk tied to that same fixed number. Nobody has disclosed the expected timeline to closing or the specific regulatory bodies whose approval is required, so the gap between signing and completion is an open window where deal risk, financing risk, and market risk all sit unresolved.
The US$700 million earnout tied to ITM-11 milestones is the clearest signal of where the real uncertainty lives. Telix is not paying full value upfront for that asset. Instead it is deferring a large chunk of consideration until clinical or regulatory progress is proven, which protects Telix's cash position but also means ITM shareholders carry execution risk on a program that has not yet delivered the outcomes the earnout is keyed to. Operators inside both companies should expect integration planning to start before any milestone is hit, since due diligence teams rarely wait for contingent payments to resolve themselves.
What breaks this deal is not exotic. Shareholder votes can fail, regulators can delay, and financing markets can reprice Telix's willingness to issue US$1.25 billion in stock if its share price moves before close. None of those outcomes are disclosed as likely or unlikely in the announcement. The company states the agreement is signed and the terms are fixed as described. It does not state a closing date.
Investors tracking this should watch the next regulatory filing for a shareholder meeting date. That date will set the real clock.